Entry Detail
| General information | |
| Database: | DB00090 |
| Objective: | Platinumbased chemotherapy with bevacizumab is a standard therapy for patients with stage IIIB/IV non small cell lung cancer with nonsquamous (NS) histology. Mechanisms of resistance to bevacizumab include increased VEGF signaling or activation of VEGF receptors. Pazopanib is a multitargeted VEGF receptor tyrosine kinase with single agent activity in non small cell lung cancer. |
| Authors: | theyiss JM, et al |
| Title: | A singlearmphase II trial of pazopanib in patients with advanced non small cell lung cancer with nonsquamous histology with disease progression on bevacizumab containing therapy. |
| Journal: | Lung Cancer. |
| Year: | 2014 |
| PMID: | 25201721 |
| Trial Design | |
| Clinical Trial Id: | NCT01262820 |
| Agent: | pazopanib |
| Target: | Plateletderived growth factor receptor Mast/stem cell growth factor receptor Vascular endothelial growth factor receptor 2 |
| Cancer Type: | non small cell lung cancer |
| Cancer Subtype: | advanced non small cell lung cancer |
| Therapy Type: | mono |
| Therapeutic Combination Type: | NA |
| Therapeutic Combination Content: | NA |
| Study Type: | A singlearmphase II trial |
| Key Patients Feature: | Stage IIIB/IV patients with adequate organ function, who progressed on a bevacizumab containing therapy |
| Biomarker: | NA |
| Biomark Analysis: | NA |
| Control Group Info: | single arm |
| Treatment Info: | Patients who were enrolled and eligible for the trial were treated with pazopanib 800 mg daily. Cycle duration was 21 days. |
| Primary End Point: | disease control rate (DCR) |
| Secondary End Point: | NA |
| Patients Number: | 15 |
| Trial Results | |
| DLT_MTD: | NA |
| Objective Response Rate: | NA |
| Disease Control Rate: | 4 discontinued therapy prior to cycle 2 evaluation due to adverse events (n=3) and medical illness (n=1), 5 patients had progressive disease, 4 patients had stable disease for <12 weeks, and 2 patients had stable disease for more than and equal to 12 weeks. No responses were observed. The DCR observed was 13% (2/15) |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | NA |
| Median OS A vs. C: | NA |
| Adverse Event(agent arm): | Episodes of grade 3 treatment related toxicities observed included: increased ALT (n=2), increased AST (n=1), anorexia (n=3), fatigue (n=3), hypertension (n=1), infection (n=1), mucositis (n=2), nausea (n=3), pericardial effusion (n=1), and vomiting (n=1). |
| Conclusions: | Pazopanib has limited activity in non small cell lung cancerNS in patients who have experienced disease progression on bevacizumab. |